Ipsen CEO David Loew (Business Wire)
Ipsen is dishing out $28 million upfront to IRLAB with $335 million in potential biobucks to nab a midstage Parkinson s disease therapy, digging deeper into the difficult brain disorder that has previously stymied the French pharma.
Mesdopetam is currently in a phase 2b trial, which will be completed by IRLAB. Ipsen will then take over phase 3 duties and all other remaining clinical development and global commercialization responsibilities, should the treatment get the green light. The company will get exclusive worldwide rights to the treatment as part of the deal.
If the drug hits the market, Swedish pharma IRLAB will get tiered low double-digit royalties on net sales.
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson s Disease
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
First European patients dosed in IRLAB s Phase IIb/III mesdopetam study
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
First European patients dosed in IRLAB s Phase IIb/III mesdopetam study
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.